Startseite>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>MBM-17

MBM-17

Katalog-Nr.GC36552

MBM-17 ist ein potenter Inhibitor der NIMA-verwandten Kinase 2 (Nek2) mit einem IC50 von 3 nM. Es hemmt wirksam die Proliferation von Krebszellen, indem es den Zellzyklusarrest und die Apoptose induziert. MBM-55 zeigt AntitumoraktivitÄten und keine offensichtliche ToxizitÄt fÜr MÄuse.

Products are for research use only. Not for human use. We do not sell to patients.

MBM-17 Chemische Struktur

Cas No.: 2083621-90-1

Größe Preis Lagerbestand Menge
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MBM-17 (compound 42c) is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice[1]. IC50: 3 nM (Nek2), 5800 nM (Aurora A)[1]

MBM-17 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.48, 1.06, 4.53 μM, respectively[1].

[1]. Xi JB, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017 Jan 27;126:1083-1106.

Bewertungen

Review for MBM-17

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MBM-17

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.